Neurotrope (NTRP) Comments on Results from Lilly's (LLY) Solanezumab Phase 3 in Alzheimer's disease

November 23, 2016 9:50 AM

Neurotrope, Inc. (OTC: NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, issued a statement ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found